A detailed history of Center For Financial Planning, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Center For Financial Planning, Inc. holds 1,757 shares of BMY stock, worth $70,385. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,757
Previous 1,416 24.08%
Holding current value
$70,385
Previous $72,000 31.94%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 25, 2024

BUY
$47.98 - $54.4 $16,361 - $18,550
341 Added 24.08%
1,757 $95,000
Q3 2023

Oct 24, 2023

BUY
$57.89 - $64.73 $13,083 - $14,628
226 Added 18.99%
1,416 $82,000
Q2 2023

Aug 09, 2023

SELL
$63.71 - $70.74 $19,113 - $21,222
-300 Reduced 20.13%
1,190 $76,000
Q4 2022

Jan 27, 2023

SELL
$68.48 - $81.09 $479 - $567
-7 Reduced 0.47%
1,490 $0
Q3 2022

Oct 14, 2022

SELL
$0.13 - $76.84 $25 - $15,137
-197 Reduced 11.63%
1,497 $106,000
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $13,797 - $15,196
190 Added 12.63%
1,694 $130,000
Q4 2021

Feb 08, 2022

SELL
$53.63 - $62.52 $180,411 - $210,317
-3,364 Reduced 69.1%
1,504 $94,000
Q3 2021

Oct 27, 2021

BUY
$59.17 - $69.31 $59 - $69
1 Added 0.02%
4,868 $288,000
Q1 2021

May 10, 2021

BUY
$59.34 - $66.74 $5,043 - $5,672
85 Added 1.78%
4,867 $307,000
Q4 2020

Feb 09, 2021

BUY
$57.74 - $65.43 $3,233 - $3,664
56 Added 1.18%
4,782 $297,000
Q2 2020

Aug 06, 2020

SELL
$54.82 - $64.09 $20,996 - $24,546
-383 Reduced 7.5%
4,726 $278,000
Q1 2020

May 11, 2020

SELL
$46.4 - $67.43 $34,846 - $50,639
-751 Reduced 12.82%
5,109 $285,000
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $288,370 - $376,153
5,860 New
5,860 $376,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $85.2B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Center For Financial Planning, Inc. Portfolio

Follow Center For Financial Planning, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Center For Financial Planning, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Center For Financial Planning, Inc. with notifications on news.